Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Extended therapy with rituximab reduces incidence of AAV relapse

16 Jun 2020

Long-term therapy with biannual infusions of rituximab over 18 months, compared with standard maintenance therapy, results in a lower incidence of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse, a study has shown.

This randomized controlled trial was carried out in 39 clinical centres in France. The investigators identified 69 patients with granulomatosis with polyangiitis (GPA) and 29 with microscopic polyangiitis (MPA) who achieved complete remission after the first phase of maintenance therapy.

From March 2015 to April 2016, 97 patients (mean age, 63.9 years; 35 percent women) were randomly assigned to receive either rituximab (n=50) or placebo infusion (n=47) every 6 months for 18 months (four infusions).

At month 28, relapse-free survival estimates stood at 96 percent (95 percent confidence interval [CI], 91–100) in the rituximab group and 74 percent (95 percent CI, 63–88) in the placebo group, with an absolute difference of 22 percent (95 percent CI, 9–36) and a hazard ratio of 7.5 (95 percent CI, 1.67–33.7; p=0.008). Major relapse-free survival estimates were 100 percent (95 percent CI, 93–100) vs 87 percent (95 percent CI, 78–97 percent), respectively (p=0.009).

At least one serious adverse event (SAE) was reported in 12 patients (24 percent) in the rituximab group (with nine infectious SAEs occurring among six patients) and in 14 patients (30 percent) in the placebo group (with six infectious SAEs developing among four patients). Of note, none of the patients died in either group.

This study was limited by potential selection bias based on previous rituximab response and tolerance, according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.